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Background: ATM and ATR are kinases implicated in a myriad of DNA-damage responses. ATM kinase inhibition
radiosensitizes cells and selectively kills cells with Fanconi anemia (FA) gene mutations. ATR kinase inhibition sensitizes
cells to agents that induce replication stress and selectively kills cells with ATM and TP53 mutations. ATM mutations and
FANCF promoter-methylation are reported in lung carcinomas.
Methods: We undertook functional analyses of ATM, ATR, Chk1 and FA proteins in lung cancer cell lines. We included
Calu6 that is reported to be FANCL-deficient. In addition, the cancer genome atlas (TCGA) database was interrogated
for alterations in: 1) ATM, MRE11A, RAD50 and NBN; 2) ATR, ATRIP and TOPBP1; and 3) 15 FA genes.
Results: No defects in ATM, ATR or Chk1 kinase activation, or FANCD2 monoubiquitination were identified in the lung
cancer cell lines examined, including Calu6, and major alterations in these pathways were not identified in the TCGA
database. Cell lines were radiosensitized by ATM kinase inhibitor KU60019, but no cell killing by ATM kinase inhibitor
alone was observed. While no synergy between gemcitabine or carboplatin and ATR kinase inhibitor ETP-46464 was
observed, synergy between gemcitabine and Chk1 kinase inhibitor UCN-01 was observed in 54 T, 201 T and H460, and
synergy between carboplatin and Chk1 kinase inhibitor was identified in 201 T and 239 T. No interactions between ATM,
ATR and FA activation were observed by either ATM or ATR kinase inhibition in the lung cancer cell lines.
Conclusions: Analyses of ATM serine 1981 and Chk1 serine 345 phosphorylation, and FANCD2 monoubiquitination
revealed that ATM and ATR kinase activation and FA pathway signaling are intact in the lung cancer cell lines examined.
As such, these posttranslational modifications may have utility as biomarkers for the integrity of DNA damage signaling
pathways in lung cancer. Different sensitization profiles between gemcitabine and carboplatin and ATR kinase inhibitor
ETP-46464 and Chk1 kinase inhibitor UCN-01 were observed and this should be considered in the rationale for Phase I
clinical trial design with ATR kinase inhibitors.
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Ataxia telangiectasia mutated (ATM) and ATM and Rad3-
related (ATR) are kinases implicated in a myriad of DNA
damage responses [1]. Somatic mutations in ATM were
identified previously in 14 of 188 lung adenocarcinomas
(7 %) [2]. While the functional significance of the ATM
mutations identified has not been determined, ATM poly-
morphisms are known to affect lung cancer risk [3]. Fur-
ther, since ataxia telangiectasia individuals with mutations* Correspondence: bakkenistcj@upmc.edu
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kinase inhibition is expected to increase the efficacy of
radiotherapy [4, 5]. Consistent with this expectation,
three small-molecule, selective ATM kinase inhibitors
radiosensitize cells in vitro [6–9]. Thus, up to 7 % of
lung adenocarcinomas that have acquired somatic mu-
tations that inactivate ATM may respond extremely
well to radiotherapy, while lung cancers that express
functional ATM are anticipated to be radiosensitized
by ATM kinase inhibitors.
ATM kinase inhibitors also kill cell lines with mutations
in genes that cause Fanconi anemia (FA), a multigenic dis-
order characterized by extreme sensitivity to interstrand
crosslinks (ICLs), with greater efficacy than complementede is distributed under the terms of the Creative Commons Attribution 4.0
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through promotor methylation of FANCF was identified
previously in 22 of 158 non-small-cell lung carcinomas
(NSCLCs) (14 %) [12]. Thus, up to 14 % of NSCLCs
may respond to single agent therapy with an ATM kin-
ase inhibitor.
In contrast to ATM, ATR is an essential protein in mice
and ATR disruption by genetic means kills human cells
in vitro [13]. However, Seckel syndrome individuals have a
mutation in a splice site that results in the expression of
just 10 % of the typical levels of ATR protein, which allows
them to survive [14]. Since cells derived from Seckel syn-
drome individuals are extremely sensitive to mitomycin C
(MMC) and ultraviolet radiation, ATR kinase inhibition is
expected to increase the efficacy of chemotherapeutics
that induce replication stress. Consistent with this ex-
pectation, three small-molecule selective ATR kinase
inhibitors sensitize cells to agents that induce replica-
tion stress in vitro [15–17]. ATR kinase inhibitors also
kill cell lines with mutations in either ATM or TP53 with
greater efficacy than complemented control cell lines. Thus,
up to 7 % of lung adenocarcinomas that have acquired
somatic mutations that inactivate ATM may respond to
single agent therapy with an ATR kinase inhibitor.
Here we sought to elucidate whether the ATM, FA and
ATR pathways interact with each other and whether the
ATM, FA and ATR pathways may be new diagnostic and
therapeutic biomarkers for lung cancer.
Materials and methods
Ethics
No research involving human subjects or human material
is described in this manuscript.
Cell culture
54 T, 201 T and 239 T are NSCLC cell lines generated from
primary patient tissues at the University of Pittsburgh [18].
H460 and Calu6 were purchased from American Type
Culture Collection (ATCC). Cells were treated with 0.2 μM
MMC, 0.1 μM gemcitabine or carboplatin (Sigma Aldrich,
St. Louis, MO). ATM kinase inhibitors KU55933 [6] and
KU60019 [7] (AstraZeneca, Macclesfield, UK) were used at
final concentrations of 10 μM and 1 μM, respectively. ATR
kinase inhibitor ETP-46464 was used at a final concen-
tration of 10 μM [15]. ETP46464 was synthesized at
the Medicinal Chemistry Shared Resource of the Ohio
State University Comprehensive Cancer Center (Columbus,
OH). Cells were γ-irradiated in a Shepherd Mark I Model
68 [137Cs] irradiator (J.L. Shepherd & Associates, San
Fernando, CA) at a dose rate of 71.1 Rad/min.
Immunoblotting
Rabbit monoclonal anti-ATM 1981S-P (EP1890Y, Epi-
tomics, Burlingame, CA), mouse monoclonal anti-ATMantisera (MAT3-4G10/8, Sigma-Aldrich, St. Louis, MO),
anti-p53 15S-P (9284, Cell Signaling Technology, Danvers,
MA), anti-p53 (sc6243-G, Santa Cruz Biotechnology, Santa
Cruz, CA), anti-Chk1 S345-P (2348S, Cell Signaling), and
anti-Chk1 2G1D5 (2360, Cell Signaling) were used. Whole
cell extracts were prepared in: 50 mM Tris-HCl pH 7.5,
150 mM NaCl, 50 mM NaF, 1 % Tween-20, 0.5 % NP40
and 1 × protease inhibitor mixture (Roche Applied Science,
Indianapolis, IN).
Clonogenic survival assays
Cells were prepared in suspension and treated with
KU60019 and increasing doses of ionizing radiation (IR).
Drug treatments were removed 17 h post-IR. After 10 days,
colonies were stained with crystal violet stain. All experi-
ments were performed in triplicate.
Proliferation assays
MTT Assay (Trevigen, Gaithersburg, MD) was used to
measure cell proliferation. Drug combinations were evalu-
ated using CalcuSyn (BIOSOFT, Ferguson, MO) software
based on the multiple drug effect equation of Chou-Talalay.
Experimental values were imputed into Calcusyn to calcu-
late IC50 and a combination index (CI, a quantitative
measure of the synergy (CI < 1), additivity (CI = 1), or
antagonism (CI > 1) between drugs).
Log-transformed CI’s are plotted against growth
inhibition/effective dose (ED) with corresponding 95 %
confidence intervals. Synergism is indicated when the
95 % CI falls below the x-axis (log CI = 0; CI = 1), whereas
antagonism is indicated when the 95 % CI falls above the
x-axis, at each respective region of the effective dose.
TCGA analyses
Analyses were undertaken using the cBio Cancer Gen-
omics Portal at Memorial Sloane Kettering Cancer Center
[19]. At the time of writing, the following analyses had
been completed on this dataset: sequenced, 183; array-
comparative genomic hybridization (aCGH), 179; tumor
RNA-seq, 178; tumor mRNA microarray, 154; tumor
miRNA, 317; and methylation, 133.
Results
Functional analyses of ATM kinase activity in lung cancer
cell lines
ATM serine 1981 phosphorylation is associated with ATM
kinase activity, and alterations in ATM, MRE11A, RAD50
and NBN may disrupt this biomarker for functionality of
ATM kinase activation mechanisms [20]. ATM kinase-
dependent, ATM serine 1981 phosphorylation was induced
by IR in all cell lines (Fig. 1a). Mechanisms of ATM kinase
activation as determined by ATM serine 1981phosphoryl-
ation are thus intact in these cell lines.
Fig. 1 a: The kinase activity of ATM was increased in lung cancer cell lines exposed to IR. Exponentially dividing lung cancer cell lines were
exposed to ATM kinase inhibitor KU60019 (ATMi) for 15 min. Cells were exposed to 2 Gy IR. Whole cell extracts were prepared at 1 h post-IR, resolved
and immunoblotted as indicated. b: FANCD2 was covalently modified in lung cancer cell lines exposed to an agent that induces ICLs. Exponentially
dividing lung cancer cell lines were exposed to 100 nM MMC and KU60019 for 18 h. Whole cell extracts were prepared and immunoblotted
as indicated. ICL-induced FANCD2 mobility shift (arrow) is seen in all the lung cancer cell lines examined and this shift is not inhibited by ATM
kinase inhibitor
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Mutations in Cancer (COSMIC) Cell Lines Project at the
Sanger Center, Cambridge, UK and has a homozygous mis-
sense point mutation (R196*) in TP53. Of the other cell
lines, H460 is a large cell carcinoma with wild-type TP53,
201 T is a lung adenocarcinoma with wild-type TP53, and
54 T and 239 T are lung squamous cell carcinomas with
wild-type TP53. We selected lung cancer cell lines with
wild-type TP53 for this study as we sought to identify the
somatic mutations that compromised ATM and ATR
kinase-dependent signaling to p53. ATM kinase-dependent
IR-induced p53 serine 15 phosphorylation was seen in
54 T, 201 T, 239 T and H460 (Fig. 1a).
Functional analyses of the FA pathway in lung cancer cell
lines
A complex of FANCA, FANCB, FANCC, FANCE, FANCF,
FANCG, FANCL, and FANCM comprise the FA core com-
plex that monoubiquitinates FANCD2 and FANCI follow-
ing DNA damage [21]. Monoubiquitinated FANCD2 can
be resolved from unmodified FANCD2 in SDS-PAGE and
this “bandshift” is a biomarker for the functionality of
the FA core complex. ICL-induced monoubiquitinated
FANCD2 was observed in all cell lines (Fig. 1b). FA
core functionality is thus intact in all cell lines. This
data conflicts with a previous report that ICL-induced
monoubiquitinated FANCD2 and FANCL protein were
not detected in Calu6 [12]. We submitted our Calu6 to
ATCC for authentication and 100 % of the markersexamined were coincident between our Calu6 and those at
the ATCC. We purchased new Calu6 cells from the ATCC.
ICL-induced monoubiquitinated FANCD2 was observed in
the new Calu6. We conclude that FA core functionality is
intact in Calu6.Analyses of lung cancer cell line killing by ATM kinase
inhibitors and IR
ATM kinase inhibitors radiosensitize cells in vitro [6–9].
ATM kinase inhibitors also kill cell lines containing muta-
tions in FA genes [11]. While ATM kinase inhibitor radio-
sensitized 201 T, 239 T, Calu6 and H460, ATM kinase
inhibitor did not kill lung these lung cancer cell lines
in the absence of exogenous DNA damage (Additional
file 1: Figure S1). 54 T is not included in these data since
these cells did not form colonies.Functional analyses of ATR kinase activity in lung cancer
cell lines
While ATM kinase activity is increased in response to
DSBs, ATR kinase activity is increased by replication
stress. However, from a therapeutic perspective these
two kinases interact as ATM kinase inhibition causes
DSBs to accumulate in cells and these activate ATR kinase
as they are repaired by homologous recombination repair
(HRR). Further, ATR kinase inhibition causes stalled repli-
cation forks to collapse and these activate ATM kinase
when they are cleaved by endonucleases.
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serine-345 is required for Chkl activation, and alterations
in ATR, ATRIP and TOPBP1 may disrupt this biomarker
for functionality of ATR kinase activation mechanisms
[22]. ATR kinase-dependent Chk1 serine-345 phosphor-
ylation was induced by gemcitabine in all cell lines (Fig. 2).
Mechanisms of ATR kinase activation are thus intact in
these cell lines. While ATR kinase inhibitor disrupts
gemcitabine-induced Chk1 serine 345 phosphorylation,
gemcitabine-induced ATM serine 1981 phosphorylation
is not disrupted in 54 T, 239 T, Calu6 or H460 by either
ATM or ATR kinase inhibitor (Fig. 2). ATM serine 1981
phosphorylation is ATM kinase-dependent in cells ex-
posed to agents that induce DSBs [20]. However, ATM
serine 1981 phosphorylation has been shown to require
ATR in cells exposed to agents that induce stalled replica-
tion forks [23]. It is possible that gemcitabine-induced
ATM serine 1981 phosphorylation is both ATM and ATR
kinase-dependent in these lung cancer cell lines and that
inhibition of either kinase is insufficient to significantlyFig. 2 ATR kinase-dependent, Chk1 serine-345 phosphorylation was induce
cell lines were exposed to gemcitabine and ATR kinase inhibitor ETP-46464 (A
were prepared, resolved and immunoblotted as indicatedreduce the phosphorylation. It is also possible that ATM is
phosphorylated by a different class of kinase and a recent
report that IKKβ phosphorylates ATM on serine 1981 in
cells exposed to alkylating agents is provocative [24].
Analyses of lung cancer cell line killing by ATR kinase
inhibitors and gemcitabine
We were interested to investigate cell killing by ATR kinase
inhibitor. We employed gemcitabine as a DNA damaging
agent to induce stalled replication forks that are not associ-
ated with ICLs. This was because we were initially con-
cerned that ICLs would accumulate in FA-deficient lung
cancer cell lines. We employed both ATR and Chk1 kinase
inhibitors since these kinases are in the same signaling
pathway. Synergy in cell killing was seen between gem-
citabine and Chk1 kinase inhibitor (UCN-01) in 54 T,
201 T and H460 at the higher response range (Fig. 3,
Additional file 2: Table S1). Chk1 kinase inhibition was
recently reported to increase sensitivity to gemcitabine
in two p53 mutant NSCLC cell lines with either highd by gemcitabine in all cell lines. Exponentially dividing lung cancer
TRi) or ATM kinase inhibitor KU55933 (ATMi) for 4 h. Whole cell extracts
Fig. 3 Synergy in cell killing was seen between gemcitabine and
Chk1 kinase inhibitor (UCN-01) in 54 T, 201 T, at the higher response
range, and H460 (Fig. 6, Table 1). However, no synergy was seen
between gemcitabine and ATR kinase inhibitor (ETP-46464).
Exponentially dividing lung cancer cell lines were treated with
increasing doses of gemcitabine, ATR kinase inhibitor ETP-46464
and Chk1 kinase inhibitor UCN-01 for 48 h and MTT reagent was
then added. Calcusyn was used to calculate a combination index
(CI), a quantitative measure of the synergy (CI < 1), additivity (CI =1),
and antagonism (CI > 1) between drugs. Log-transformed combination
indices (CI) are plotted against growth inhibition/effective dose (ED)
with corresponding 95 % confidence interval for a representative
experiment. Representative examples from at least 3 experiments
are shown (mean of 3 replicates)
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was seen between gemcitabine and ATR kinase inhibitor.
Thus, ATR kinase inhibitor ETP-46464 and Chk1 inhibi-
tor UCN-01 do not phenocopy each other in combination
with gemcitabine.
Analyses of lung cancer cell line killing by ATM kinase
inhibitors and gemcitabine
We were also interested in how cell killing by gemcitabine
would be affected by ATM kinase inhibition. We reasoned
that gemcitabine might induce DSBs in lung cancer cell
lines due to acquired mutations that disrupt mechanismsthat protect stalled replication forks. If this were the case
then increased cell killing might be seen with gemcitabine
and ATM kinase inhibitor but not gemcitabine and ATR
kinase inhibitor. However, gemcitabine was not potenti-
ated by ATM kinase inhibition (Fig. 4, Additional file 2:
Table S2). Thus, the lesions induced by gemcitabine and
ATM kinase inhibition do not interact in the lung cancer
cell lines examined.
Analyses of lung cancer cell line killing by ATR kinase
inhibitors and carboplatin
Since the FA pathway was intact in all the cell lines ex-
amined we used carboplatin to induce stalled replication
forks at ICLs. Synergy in cell killing was seen between
carboplatin and Chk1 inhibitor in 239 T at the higher dose
range and in 201 T (Fig. 5, Additional file 2: Table S3).
Thus, while no synergy between gemcitabine or carboplatin
and ATR inhibition was observed in the lung cancer cell
lines used here, synergy between gemcitabine and Chk1 in-
hibition was observed in 54 T, 201 Tand H460, and synergy
between carboplatin and Chk1 inhibition was identified in
201 T and 239 T. This contrasts with a recent report that
shows synergy between carboplatin and ATR kinase inhibi-
tor ETP-46464 in ovarian cancer cell lines [26] and data
that documents synergy between carboplatin and another
ATR kinase inhibitor [17]. Chk1 kinase inhibition, but not
ATR kinase inhibition, blocks a mechanism(s) that is essen-
tial for survival in certain lung cancer cell lines treated with
either gemcitabine or carboplatin.
Analyses of ATM, FA, and ATR alterations in 212 lung
squamous cell carcinomas (TCGA)
Mechanisms of ATM and ATR kinase activation and FA
core functionality are intact in the cell lines examined.
To extend these findings we interrogated the publically
available database of 212 lung squamous cell carcinomas
in the TCGA to determine the incidence of alterations
that are predicted to compromise ATM and ATR kinase
activation and the FA pathway of ICL repair. ATM kinase
activation following low doses of IR requires the MRE11A,
RAD50 and NBN complex [27, 28]. The TCGA data-
base contains 9 missense point mutations in ATM, 3 in
MRE11A, 4 in RAD50, and 1 in NBN (Fig. 6a, c). ATM
and MRE11A are each amplified in a single carcinoma.
MRE11A and RAD50 homozygous deletion are each iden-
tified in carcinomas. This is noteworthy because MRE11A
and RAD50 are essential genes in mice [29, 30]. Together
these 4 genes that are required for ATM kinase activation
are altered in 20/212 (9 %) of lung squamous cell
carcinomas (TCGA).
ATR activation requires ATRIP and TOPBP1 [31, 32].
The TCGA database contains 13 missense point muta-
tions in ATR, 3 in ATRIP, and 7 in TOPBP1 (Fig. 6b, d).
ATR (located on human chromosome 3q22-q24) and
Fig. 4 No synergy was seen between gemcitabine and ATM kinase
inhibitor. Exponentially dividing lung cancer cell lines were treated
with increasing doses of gemcitabine and a fixed concentration of
ATM kinase inhibitor KU55933 for 48 h and MTT reagent was then
added. Representative examples from at least 3 replicate experiments
are shown (mean, SD of 4 replicates)
Fig. 5 Synergy in cell killing was seen between carboplatin and
Chk1 kinase inhibitor (UCN-01) in 239 T, at the higher response range,
and 201 T. However, synergy was only seen in 54 T between carboplatin
and ATR kinase inhibitor (ETP-46464) at the lower dose range.
Exponentially dividing lung cancer cell lines were treated with
increasing doses of carboplatin, ATR kinase inhibitor ETP-46464
and Chk1 kinase inhibitor UCN-01 for 48 h and MTT reagent was
then added. Calcusyn was used to calculate a combination index
(CI), a quantitative measure of the synergy (CI < 1), additivity (CI =1),
and antagonism (CI > 1) between drugs. Log-transformed combination
indices (CI) are plotted against growth inhibition/effective dose (ED)
with corresponding 95 % confidence interval for a representative
experiment. Representative examples from at least 3 experiments
are shown (mean of 3 replicates)
Beumer et al. BMC Cancer  (2015) 15:649 Page 6 of 10TOPBP1 (located on human chromosome 3q22.1) are
co-amplified in 11 carcinomas. TOPBP1 and ATR are amp-
lified independently in 1 and 12 carcinomas, respectively.
ATRIP homozygous deletion is identified in two carcin-
omas. This is noteworthy because homozygous loss-of-
function of ATRIP is not compatible with mammalian
cell viability. Together these 3 genes that are required
for ATR kinase activation are altered in 45/212 (21 %)
of lung squamous cell carcinomas (TCGA). The strik-
ing conclusion from these analyses is that while ATM is
mutated in a subset of lung cancers, ATR is amplified
in subset of lung cancers.
Fig. 6 a. Alterations in ATM, MRE11A, RAD50 and NBN were identified in 212 lung squamous cell carcinomas (TCGA). Amplification, homozygous deletion
and mutation are shown. b. Alterations in ATR, ATRIP and TOPBP1. c. Mutations in ATM. d. Mutations in ATR. G736* occurs in two independent carcinomas
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that resolves ICLs encountered by DNA replication forks.
Together the 15 FA genes are altered by missense point
mutation, amplification or homozygous deletion in 72/212
(34 %) of lung squamous cell carcinomas in the publically
available TCGA database (Additional file 3: Figure S1).
The only FA proteins in which missense point mutations
are not identified were FANCD2 and RAD51C. The data
are summarized as follows: 6 missense point mutations in
FANCA; 4 in FANCB; 2 in FANCC; 1 in FANCE; 3 in
FANCF; 5 in FANCG; 1 in FANCL; 10 in FANCM; 1 in
FANCI; 12 in BRCA2; 6 in BRIP1; 6 in PALB2 (FANCN);
and 14 in SLX4 (FANCP). Amplifications of 8 FA genes
are identified across 22 carcinomas; 2 of the carcinomas
contain amplification in two FA genes (FANCG with
FANCI and BRIP1 with RAD51C). FANCG, PALB2 and
SLX4 homozygous deletions are identified in single carcin-
omas while FANCM homozygous deletions are identified
in 2 carcinomas. This is noteworthy because while Fancg,
Fancm and Slx4 are not essential for viability [33–35],
Palb2 is embryonically essential in mice [36].
Since inactivation of the FA pathway through methyla-
tion of the FANCF promoter was identified previously in
22 of 158 NSCLCs (14 %), we also examined mRNA ex-
pression levels for the FA genes in lung squamous cell
carcinomas in the publically available TCGA database. To-
gether the 15 FA genes are altered by missense point muta-
tion, amplification, homozygous deletion, up-regulation
(RNA), and down-regulation (RNA) in 102/212 (48 %) of
lung squamous cell carcinomas (TCGA) (Additional file 3:
Figure S1). In line with the reported inactivation of the FA
pathway through methylation of the FANCF promoter [12],down-regulation of FANCF RNA is identified in 5/212 lung
squamous cell carcinomas in the publically available
TCGA database.
Discussion
Somatic mutations in ATM have been identified previ-
ously in 14 of 188 lung adenocarcinomas (7 %) (2). ATM
kinase activation and signaling were normal in the lung
cancer cell lines examined here. Missense point mutations
of ATM in 9/212 lung squamous cell carcinomas (4 %) are
present in the TCGA database. These heterozygous muta-
tions span the gene and aside from one mutation in the
phosphatidylinositol 3-kinase domain (G2897S) none are
judged likely to have a significant impact on kinase activity
or expression. Missense point mutations in an extended
analysis of ATM, MRE11A, RAD50 and NBN are present
in 16/212 lung squamous cell carcinomas (7 %) are
present in the TCGA database. None of the missense
point mutations in MRE11A, RAD50 and NBN are judged
likely to have a significant impact on ATM kinase activity
or expression. Thus, our analysis does not suggest that a
significant number of lung squamous cell carcinomas will
be radiosensitive as a result of acquired missense point
mutations that affect ATM kinase activation.
Inactivation of the FA pathway through promotor
methylation of FANCF was also identified previously in
22 of 158 non-small-cell lung carcinomas (NSCLCs)
(14 %) [12]. FA pathway activation was normal in the
lung cancer cell lines examined here. Down-regulation of
FANCF mRNA is present in only 5/212 lung squamous
cell carcinomas (2 %) in the publically available TCGA
database. Together missense point mutation, amplification
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in 72/212 lung squamous cell carcinomas (34 %) in the
TCGA database. Of the 52 missense point mutations in
the 15 FA genes, 4 generate stop codons. None of the
remaining missense point mutations are predicted to
have a “high” impact on protein function. In summation,
our analysis does not suggest that a significant number of
lung squamous cell carcinomas will be sensitive to ICLs as
a result of acquired missense point mutations that affect
FA gene products.
Carcinomas with homozygous deletions in either
MRE11A, RAD50, ATRIP or PALB2, 4 genes that are
essential for mammalian cell viability, are present in the
publically available TCGA database. These data were
derived using GISTIC, a copy-number analysis algorithm
and are defined by “-2,” deep loss, possible homozygous
deletion. The simplest biological explanation for these ob-
servations is that the carcinomas are heterogenous and
contain two populations of cells that have lost different al-
leles of the gene. It is unlikely transformed cells can survive
without MRE11A, RAD50, ATRIP or PALB2 although sig-
nificantly reduced levels may be tolerated, as evidenced by
the ATR expression in Seckel syndrome and hypomorphic
MRE11A and RAD50 mutations in ATLD and NBS-like
disorder patients, respectively [37, 38].
ATR, ATRIP and TOPBP1 are altered in 45/212 lung
squamous cell carcinomas (21 %) in the TCGA database.
One frame-shift mutation, one point mutation G736* (in
two independent carcinomas), and one point mutation
D1687H in ATR are likely to reduce ATR activity. In
contrast, the co-amplification of ATR (located on human
chromosome 3q22-q24) and TOPBP1 (located on human
chromosome 3q22.1) in 11 carcinomas may increase ATR
activity. These data were derived using GISTIC, a copy-
number analysis algorithm and are defined by “+2,” high-
level amplification, possible amplification and as such are
subject to similar error as the data describing homozygous
deletion. However, the co-amplification of ATR and
TOPBP1 may serve as independent experimental vali-
dations of amplification of chromosome 3q22-q24. Cer-
tainly, amplification of ATR and TOPBP1 has been
separated in other carcinomas and the trend in the TCGA
database is towards inactivation of ATM kinase signaling
and increased ATR kinase signaling (Fig. 6).
Oncogene-induced replication stress activates the ATR
pathway in many neoplasias including lung [39, 40]. There-
fore, the ATR kinase signaling may be a tumor suppressor
mechanism. However, alterations that compromise ATR
kinase signaling may be selected against since transformed
cells may have an increased dependency on the ATR path-
way, analogous to oncogene addiction, to continue to
replicate and divide in the presence of replication stress.
However, and in contrast to expectations, no synergy be-
tween gemcitabine or carboplatin and ATR kinase inhibitorETP-46464 was observed. In contrast synergy between
gemcitabine and Chk1 inhibition was observed in 54 T,
201 T and H460, and synergy between carboplatin and
Chk1 inhibition was identified in 201 T and 239 T. As
such, Chk1 kinase inhibition, but not ATR kinase inhib-
ition, blocks a mechanism(s) that is essential for survival
in some lung cancer cell lines treated with either gemcita-
bine or carboplatin. Different sensitization profiles be-
tween ATR kinase and Chk1 kinase inhibitors have been
recently published in ovarian cancer cell lines using ATR
kinase inhibitor VE-821 [41], and lung cancer cell lines
using ATR kinase inhibitor VE-822 and Chk1 kinase in-
hibitor AZD7762 [42]. Our data may be attributed to a
Chk1 kinase-dependent mechanism that is ATR kinase-
independent. Alternatively, Chk1 kinase inhibition may be
dominant inhibitory over a survival pathway where ATR
kinase inhibition is not, perhaps because an alternate
mechanism can be recruited in the absence of ATR
kinase signaling. Finally, ETP-46464 may inhibit a sig-
naling pathway, in addition to that initiated by ATR
kinase, that protects cells against the cytotoxic effects
of ATR and Chk1 kinase inhibition. In any event, our
data show that ATR kinase inhibition with ETP-46464
does not phenocopy Chk1 kinase inhibition with UCN-01
and as a consequence, ATR and Chk1 inhibitors may dif-
ferent sensitization profiles and this should be considered
in the rationale for Phase I clinical trial design with ATR
kinase inhibitors.
Conclusions
Analyses of ATM serine 1981 and Chk1 serine 345 phos-
phorylation, and FANCD2 monoubiquitination revealed
that ATM and ATR kinase activation and FA pathway sig-
naling are intact in the lung cancer cell lines examined. As
such, these posttranslational modifications may have utility
as therapeutic biomarkers for the integrity of DNA damage
signaling pathways in lung cancer. Different sensitization
profiles between gemcitabine and carboplatin and ATR
kinase inhibitor ETP-46464 and Chk1 kinase inhibitor
UCN-01 were observed and this should be considered in
the rationale for Phase I clinical trial design with ATR kin-
ase inhibitors.
Additional files
Additional file 1: Figure S1. Lung cancer cell lines were radiosensitized
by ATM kinase inhibitor. Cells were prepared in suspension and treated with
KU60019 and increasing doses of IR. Cells were seeded in 60 mm petri dishes.
Drug treatments were removed 17 h post-IR. After 10 days, colonies were
stained with crystal violet stain. A representative example of three experiments
is shown. (PDF 555 kb)
Additional file 2: Table S1. Gemcitabine, CHK1i and ATRi IC50 values
and combination indices (CI-ED50) in human lung cancer cell lines
(mean, SD). Table S2. Gemcitabine IC50 values and potentiation by ATMi
in human lung cancer cell lines (mean, SD). Table S3. Carboplatin, CHK1i
Beumer et al. BMC Cancer  (2015) 15:649 Page 9 of 10and ATRi IC50 values and combination indices (CI-ED50) in human lung
cancer cell lines (mean, SD). (DOC 47 kb)
Additional file 3: Figure S1. Alterations in 15 FA genes were identified
in 212 lung squamous cell carcinomas (TCGA). Amplification, homozygous
deletion, up-regulation RNA, down-regulation RNA and mutation are
shown. (PDF 1919 kb)
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